

HIV Vaccine Clinical Trials Pipeline

Approach		Description	Key Candidates	Trials	Funders/Developers
Neutralizing Antibody Induction		Designed to induce generalized neutralizing antibody responses, as opposed to targeting a specific bNAb response	- BG505 trimers on mRNA platform - UVAX-1107, UVAX-1197	HVTN 302, HVTN 313 HVTN 319, UVAX-HIV-101	HVTN, UVAX Bio LLC
Combined Immune Responses		Designed to induce various immune responses against HIV infection, including cellular T-cell responses and/or non-neutralizing antibody responses	- ALFQ vector-based vaccines - Ad4 vector-based intranasal vaccines - Chimp-Ad gp140 + gp120 vaccine	HVTN 139, HVTN 318, RV 546, RV 575, RV 591	HVTN, MHRP
CD8+ T-Cell Induction		Designed to induce T-cell responses to inhibit HIV replication and kill HIV-infected cells	GrAdHIVNE1, VIR-1388 HCMV	IAVI C114, VIR-1388-V101	HVTN, IAVI, Gates Foundation, Vir Biotechnology
Germline Targeting	CD4 Binding Site	Designed to initiate a bNAb response targeted to a specific site on the HIV envelope (e.g., CD4 binding site, V3 glycan, multiple) through an antibody pathway encoded by a particular germline antibody. Accomplished through a series of immunizations	- eOD-GT8 60mer - BG505 SOSIP gp140; BG505 GT1.1 426.Mod.Core-C4B - CH505 TF chTrimer	BRILLIANT-011, HVTN 300, HVTN 301 HVTN 312, HVTN 316 HVTN 320, IAVI G002 IAVI C107, IAVI C110	Access to Advanced Health Institute, Amsterdam UMC, BRILLIANT Consortium, Gates Foundation, George Washington University, HVTN, IAVI, Polymun Scientific GmbH, Rockefeller University, 3M Corporate
	V3 Glycan		N332-GT5 gp140	HVTN 144, HVTN 307 HVTN 321	HVTN
	CD4 Binding Site & V3 Glycan		- eOD-GT8 60mer mRNA + coreg28v2 60mer mRNA - N332 GT5 mRNA	G004	IAVI, Gates Foundation, Moderna, Scripps Research

All vaccine candidates shown above are currently in Phase I trials. More details can be found in AVAC's [Pipeline Tracker](#).